News for Healthier Living

Mount Sinai Study Reveals Why Some Myeloma Patients Stay Cancer-Free for Years After CAR T Therapy

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell therapy, while others see their cancer return sooner. Published in Blood Advances, the research is the first longitudinal, single-cell, multi-omic study of cilta-cel in multiple myeloma. Cilta-cel (ciltacabtagene autoleucel) is a type of CAR T cell therapy used to treat relapsed or refractory multiple myeloma. It works by using a patient's own T cells, which are genetically engineered in a lab to target and kill cancer cells that have B cell maturation antigen (BCMA) on their surface. The modified T cells are then infused back into the patient as a one-time treatment to fight the cancer.

November 12, 2025


November 15 2025

November 14 2025

November 13 2025

November 12 2025

November 11 2025

November 10 2025

November 9 2025

November 8 2025

November 7 2025

November 6 2025

November 5 2025

November 4 2025

November 3 2025

November 2 2025

November 1 2025